Theravance Biopharma, Inc. (TBPH) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
TBPH Revenue Growth
Revenue Breakdown (FY 2024)
TBPH's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
TBPH Revenue Analysis (2013–2024)
As of May 8, 2026, Theravance Biopharma, Inc. (TBPH) generated trailing twelve-month (TTM) revenue of $80.3 million, reflecting strong growth of +18.5% year-over-year. The most recent quarter (Q3 2025) recorded $20.0 million in revenue, down 23.7% sequentially.
Looking at the longer-term picture, TBPH's 5-year compound annual growth rate (CAGR) stands at -2.6%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $73.4 million in 2019.
Revenue diversification analysis shows TBPH's business is primarily driven by YUPELRI Monotherapy (56%), and Collaboration revenue (44%). With over half of revenue concentrated in YUPELRI Monotherapy, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including INVA (+13.6% YoY), PRGO (-3.6% YoY), and SUPN (+16.3% YoY), TBPH has underperformed the peer group in terms of revenue growth. Compare TBPH vs INVA →
TBPH Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| TBPHCurrent | $80M | +18.5% | -2.6% | -72.9% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% | |
 PRGO | $4.3B | -3.6% | +0.8% | 8.1% | |
 SUPN | $719M | +16.3% | +6.7% | -5.1% | |
 PCRX | $726M | +4.6% | +11.1% | 4.6% | |
 INSM | $606M | +66.7% | +29.8% | -194.0% |
TBPH Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $64.4M | +12.1% | $64.4M | 100.0% | $-46,949,000 | -72.9% |
| 2023 | $57.4M | +11.8% | $16.8M | 29.3% | $-56,035,000 | -97.6% |
| 2022 | $51.3M | -7.2% | $-12,046,000 | -23.5% | $-91,957,000 | -179.1% |
| 2021 | $55.3M | -23.0% | $-138,346,000 | -250.1% | $-257,784,000 | -466.1% |
| 2020 | $71.9M | -2.1% | $71.9M | 100.0% | $-297,627,000 | -414.2% |
| 2019 | $73.4M | +21.6% | $73.4M | 100.0% | $-251,915,000 | -343.1% |
| 2018 | $60.4M | +292.4% | $59.7M | 98.8% | $-238,751,000 | -395.5% |
| 2017 | $15.4M | -68.4% | $9.4M | 60.8% | $-260,123,000 | -1690.6% |
| 2016 | $48.6M | +15.5% | $45.8M | 94.1% | $-180,467,000 | -371.0% |
| 2015 | $42.1M | +260.4% | $37.5M | 88.9% | $-181,899,000 | -431.8% |
See TBPH's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TBPH Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TBPH vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTBPH — Frequently Asked Questions
Quick answers to the most common questions about buying TBPH stock.
Is TBPH's revenue growth accelerating or slowing?
TBPH revenue is accelerating at +18.5% year-over-year, exceeding the 5-year CAGR of -2.6%. TTM revenue reached $80M. Growth momentum has increased versus prior periods.
What is TBPH's long-term revenue growth rate?
Theravance Biopharma, Inc.'s 5-year revenue CAGR of -2.6% reflects the sustained expansion pattern. Current YoY growth of +18.5% is above this long-term average.
How is TBPH's revenue distributed by segment?
TBPH reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.